Please use this identifier to cite or link to this item:
https://www.um.edu.mt/library/oar/handle/123456789/49094| Title: | Pharmacist-led CYP2C19 genotyping in patients on clopidogrel therapy following percutaneous coronary intervention |
| Authors: | Wirth, Francesca Zahra, Graziella Xuereb, Robert G. Barbara, Christopher Fenech, Albert Azzopardi, Lilian M. |
| Keywords: | Clopidogrel Coronary heart disease -- Chemotherapy -- Malta Pharmacogenetics -- Malta Coronary arteries -- Stenosis -- Prevention |
| Issue Date: | 2015-06 |
| Publisher: | Springer Dordrecht |
| Citation: | Wirth, F., Zahra, G., Xuereb, R. G., Barbara, C., Fenech, A., & Azzopardi, L. M. (2015, June). Pharmacist-led CYP2C19 genotyping in patients on clopidogrel therapy following percutaneous coronary intervention. Nordic Social Pharmacy and Health Services Research Conference & The Nordic Networking Group for Clinical Pharmacy, Tartu, Estonia. 32-33. |
| Abstract: | Background and objectives: The 2013 Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP2C19 genotype and clopidogrel therapy[1], classify CYP2C19 genotypes into 4 metaboliser phenotypes: ‘Extensive’, carrying only normal function alleles (EMs *1/*1), ‘ultra-rapid’, carrying at least one gain-offunction allele (UMs *1/*17, *17/*17), ‘intermediate’, carrying one loss-of-function (LoF) allele (IMs *1/*2, *2/*17)’, and ‘poor’, carrying two LoF alleles (PMs *2/*2). The objective of this study was to apply a laboratory-based, pharmacist-led, process to genotype Maltese patients, who were prescribed clopidogrel therapy following percutaneous coronary intervention, for the CYP2C19 *2 and *17 variant alleles. |
| URI: | https://www.um.edu.mt/library/oar/handle/123456789/49094 |
| Appears in Collections: | Scholarly Works - FacM&SPha |
Files in This Item:
Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.